Scarica l'app Stockscreener
0.3153
7.61%
0.0223
Dopo l'orario di chiusura:
.30
-0.0153
-4.85%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.293
Aprire:
$0.291
Volume 24 ore:
12.59M
Relative Volume:
1.40
Capitalizzazione di mercato:
$17.65M
Reddito:
-
Utile/perdita netta:
$-33.36M
Rapporto P/E:
-0.4702
EPS:
-0.6706
Flusso di cassa netto:
$-23.09M
1 W Prestazione:
+43.32%
1M Prestazione:
-56.87%
6M Prestazione:
-54.09%
1 anno Prestazione:
-74.37%
Intervallo 1D:
$0.285
$0.33
Intervallo di 1 settimana:
$0.2174
$0.651
Portata 52W:
$0.1952
$1.55
Pds Biotechnology Corp Stock (PDSB) Company Profile
Nome
Pds Biotechnology Corp
Settore
Industria
Telefono
800-208-3343
Indirizzo
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
0.3153 | 16.40M | 0 | -33.36M | -23.09M | -0.6706 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-11-01 | Iniziato | B. Riley Securities | Buy |
| 2021-06-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-09 | Iniziato | Noble Capital Markets | Outperform |
| 2019-10-24 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Pds Biotechnology Corp Borsa (PDSB) Ultime notizie
PDS Biotechnology Market Sentiment - Benzinga España
Most Active Stocks on September 8: PDS Biotech, Green Circle, Mobix Labs, Intel and Nokia Lead Volume - ChartMill
Curious about the most active stocks on Tuesday? - ChartMill
12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com
PDS Biotech soars as it announces up to $22.55 million financing - The Pharma Letter
PDS Biotech Jumps as Soon-Shiong-Backed Financing Eases Funding Pressure - Quiver Quantitative
PDS Biotech raises up to USD 22.55m to advance IL-12 immunotherapy toward Phase III in CRC - AllSci
Dow Tumbles 450 Points; US Small Business Sentiment Declines In August - benzinga.com
PDS Biotechnology Announces PIPE Financing and Strategic Alignment - TipRanks
PDS Biotech raises up to $22.55M led by Nant Capital - Investing.com Canada
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks - marketscreener.com
80% survived at least two years in a 22-patient trial of PDS Biotech's cancer treatment - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
PDS Biotechnology’s Phase 3 Head and Neck Cancer Trial Termination: What It Means for Investors - TipRanks
PDS Biotech’s Lender Gets 100% of New Non-ATM Equity Cash - TechStock²
PDSB News | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Amends $6 Million Promissory Note, Tightening Repayment With YA II PN - TradingView
PDS Biotechnology (Nasdaq: PDSB) changes terms on a $6M loan - Stock Titan
Stephan Toutain removed as COO at PDS Biotechnology - TradingView
PDS Biotechnology Corp (NASDAQ: PDSB) Share Price, PDSB Stock News, PDSB Share Price & Updates - Kalkine
Form 8K PDS Biotechnology Corp For: 19 August By Investing.com - Investing.com Nigeria
PDS Biotechnology announces CFO resignation and interim appointments - Investing.com
PDS Biotechnology CFO Lars Boesgaard to Resign; Janetta Trochimiuk and Frank Bedu-Addo Appointed Interim Officers - TradingView
PDS Biotechnology (NASDAQ: PDSB) CEO takes interim finance role as CFO departs - Stock Titan
Weekly Recap: PDS0301 Phase 2 results and Q2 adjusted loss $0.18 - TradingView
PDS Biotechnology shareholders approve charter amendment and director elections - Investing.com
Form 8K PDS Biotechnology Corp For: 14 August By Investing.com - Investing.com Nigeria
PDS Biotechnology (PDSB) wins approval to double authorized stock and elect directors - Stock Titan
PDS Biotechnology (PDSB) cuts R&D spend but warns on going concern, cash at $5.6M - Stock Titan
PDSB Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
PDS Biotechnology Q2 Results: EPS misses estimate, losses widen YoY - scanx.trade
Form 8K PDS Biotechnology Corp For: 13 August By Investing.com - Investing.com South Africa
PDS Biotechnology reports Q2 2026 net loss $9.8M, cash $5.6M, strategic refocus on PDS0301 - TradingView
PDS Biotech Reports $9.8 Million Second-Quarter 2026 Net Loss - Quiver Quantitative
PDS Biotech Reports Second Quarter 2026 Financial Results - The Manila Times
PDS Biotechnology: Q2 Earnings Snapshot - Barchart.com
PDS Biotechnology Halts PDS0101 Trial, Pivots to PDS0301 in Colorectal Cancer - The Clinical Trial Vanguard
PDS Biotech Prioritizes PDS0301 After 71% Response Rate In Colorectal Cancer And Discontinues PDS0101 Phase 3 Trial - Pulse 2.0
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.34% - Investing.com
PDS Biotechnology shifts focus to PDS0301, halts PDS0101 trial By Investing.com - Investing.com South Africa
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program - Benzinga
Form 8K PDS Biotechnology Corp For: 11 August By Investing.com - Investing.com Nigeria
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 - manilatimes.net
PDS Biotechnology prioritizes PDS0301 after Phase 2 mCRC data, halts internal PDS0101 Phase 3 spend - TradingView
PDS Biotechnology shifts focus to PDS0301, halts PDS0101 trial - Investing.com
PDS Biotechnology Refocuses on PDS0301, Ends Internal Development of PDS0101 Phase 3 Trial - Quiver Quantitative
PDS0301 Data Show 80% 24-Month Survival With Liver Metastases - Stock Titan
PDS Biotechnology Corp (PDSB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PDS Biotechnology Corp expected to post a loss of 13 cents a shareEarnings Preview - TradingView
PDS Biotechnology Corp (PDSB) Stock News Today - TradingKey
PDSB Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesFull Year Guidance - vinanet.vn
Pds Biotechnology Corp Azioni (PDSB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):